Chenyang Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chenyang Jiang has a total of 438 co-authors. Here are the top co-authors by number of shared publications:
Qiang Liu
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
26 shared publicationsRuhong Jiang
Department of Cardiology Sir Run Run Shaw Hospital Zhejiang University School of Medicine Hangzhou China
23 shared publicationsLu Yu
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
18 shared publicationsGuosheng Fu
Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; Zhejiang Key Laboratory of Cardiovascular Intervention and Precision Medicine, Hangzhou, Zhejiang, China; Engineering Research Center for Cardiovascular Innovative Devices of Zhejiang Province, Hangzhou, Zhejiang, China
17 shared publicationsYaxun Sun
Department of Cardiology Sir Run Run Shaw Hospital Zhejiang University School of Medicine Hangzhou 310016 China
17 shared publicationsPei Zhang
For the PROMPT-AF investigators
15 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Oxford University Press (OUP) in EP Europace
Modified Posterior Wall Ablation in Persistent Atrial Fibrillation: the BOX-AF Randomized Clinical Trial
Aims: The efficacy of left atrial posterior wall isolation (PWI) for persistent atrial fibrillation (AF) is controversial. We propose a modified left atrial posterior wall ablation strategy. Objectives: To evaluate the efficacy and safety of modified posterior wall ablation in patients with persistent AF who underwent first-time radiofrequency catheter ablation. Methods and results: In this multicenter, single-blind randomized trial, 276 patients with persistent AF were assigned 1:1 to pulmonary vein isolation (PVI) with (BOX+) or without modified posterior wall ablation (BOX−). Seven participants withdrew, leaving 269 (BOX+, n=139; BOX−, n=130) for primary endpoint analysis. The primary endpoint was freedom from any documented atrial arrhythmia lasting > 30 seconds without antiarrhythmic drugs after a 3 -month blanking period. At 12-month follow-up, the primary endpoint occurred in 120 of 139 patients (86.3%) in the BOX+ group and 113 of 130 (86.9%) in the BOX− group (hazard ratio 1.046, 95% CI, 0.54 - 2.01; P = 0.894). The BOX+ group exhibited longer procedure time and ablation time. Acute successful PWI was achieved in 91 (65.5%) patients assigned to BOX+. In a nonprespecified, post-randomization analysis, arrhythmia-free survival was 93.4% in patients with acute successful PWI, 72.9% in those with attempted but unsuccessful PWI, and 86.9% in controls without attempted PWI (overall log-rank P=0.002). Adverse events were similar between groups. Conclusion: Routine addition of modified posterior wall ablation did not improve overall outcomes of first-time ablation in persistent AF. However, achieving successful PWI was associated with significantly lower recurrence.
- 13 November 2026
- Published by Oxford University Press (OUP) in EP Europace
Open AccessModified Posterior Wall Ablation in Persistent Atrial Fibrillation: the BOX-AF Randomized Clinical Trial
Aims: The efficacy of left atrial posterior wall isolation (PWI) for persistent atrial fibrillation (AF) is controversial. We propose a modified left atrial posterior wall ablation strategy. Objectives: To evaluate the efficacy and safety of modified posterior wall ablation in patients with persistent AF who underwent first-time radiofrequency catheter ablation. Methods and results: In this multicenter, single-blind randomized trial, 276 patients with persistent AF were assigned 1:1 to pulmonary vein isolation (PVI) with (BOX+) or without modified posterior wall ablation (BOX−). Seven participants withdrew, leaving 269 (BOX+, n=139; BOX−, n=130) for primary endpoint analysis. The primary endpoint was freedom from any documented atrial arrhythmia lasting > 30 seconds without antiarrhythmic drugs after a 3 -month blanking period. At 12-month follow-up, the primary endpoint occurred in 120 of 139 patients (86.3%) in the BOX+ group and 113 of 130 (86.9%) in the BOX− group (hazard ratio 1.046, 95% CI, 0.54 - 2.01; P = 0.894). The BOX+ group exhibited longer procedure time and ablation time. Acute successful PWI was achieved in 91 (65.5%) patients assigned to BOX+. In a nonprespecified, post-randomization analysis, arrhythmia-free survival was 93.4% in patients with acute successful PWI, 72.9% in those with attempted but unsuccessful PWI, and 86.9% in controls without attempted PWI (overall log-rank P=0.002). Adverse events were similar between groups. Conclusion: Routine addition of modified posterior wall ablation did not improve overall outcomes of first-time ablation in persistent AF. However, achieving successful PWI was associated with significantly lower recurrence.
- Open Access
ENO1-Related Signaling in Hypertension-Associated Atrial Remodeling: Evidence Implicating PI3K/AKT and NOX4
Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia worldwide; hypertension is one of the most important risk factors for AF and contributes to both its initiation and maintenance. This study investigated the contribution of enolase 1 (ENO1) to hypertension-associated atrial remodeling and susceptibility to pacing-induced AF. Long-term hypertension was associated with increased AF inducibility in rats, and atrial transcriptomic analyses at two stages of hypertension identified persistent ENO1 upregulation. ENO1 was also increased in two external human left atrial AF datasets. An angiotensin II (Ang II)-induced atrial cardiomyocyte injury model was constructed to evaluate the role of ENO1 in Ang II-induced cardiomyocyte hypertrophy. In Ang II-stimulated primary neonatal rat atrial cardiomyocytes, siRNA-mediated ENO1 knockdown attenuated hypertrophic and oxidative-stress-related changes and was accompanied by lower PI3K/AKT phosphorylation and NADPH oxidase 4 (NOX4) expression. AP-III-a4 treatment produced concordant changes in selected cellular endpoints. PI3K inhibition reduced NOX4 expression and intracellular hydrogen peroxide levels. In ENO1-silenced cardiomyocytes, PI3K activation with 740Y-P partially increased both PI3K/AKT phosphorylation and NOX4 expression. In Ang II-infused hypertensive mice, AP-III-a4 treatment reduced atrial enlargement, fibrosis, PI3K/AKT phosphorylation, NOX4 expression, and atrial reactive oxygen species signals; it also attenuated atrial effective refractory period shortening. AP-III-a4 significantly shortened the duration of pacing-induced AF and was associated with numerically lower AF inducibility, although the latter difference did not reach statistical significance. Collectively, these findings support the involvement of PI3K/AKT signaling in ENO1-associated regulation of NOX4 and suggest that this relationship may contribute to the observed attenuation of hypertension-associated atrial remodeling.
Open AccessENO1-Related Signaling in Hypertension-Associated Atrial Remodeling: Evidence Implicating PI3K/AKT and NOX4
Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia worldwide; hypertension is one of the most important risk factors for AF and contributes to both its initiation and maintenance. This study investigated the contribution of enolase 1 (ENO1) to hypertension-associated atrial remodeling and susceptibility to pacing-induced AF. Long-term hypertension was associated with increased AF inducibility in rats, and atrial transcriptomic analyses at two stages of hypertension identified persistent ENO1 upregulation. ENO1 was also increased in two external human left atrial AF datasets. An angiotensin II (Ang II)-induced atrial cardiomyocyte injury model was constructed to evaluate the role of ENO1 in Ang II-induced cardiomyocyte hypertrophy. In Ang II-stimulated primary neonatal rat atrial cardiomyocytes, siRNA-mediated ENO1 knockdown attenuated hypertrophic and oxidative-stress-related changes and was accompanied by lower PI3K/AKT phosphorylation and NADPH oxidase 4 (NOX4) expression. AP-III-a4 treatment produced concordant changes in selected cellular endpoints. PI3K inhibition reduced NOX4 expression and intracellular hydrogen peroxide levels. In ENO1-silenced cardiomyocytes, PI3K activation with 740Y-P partially increased both PI3K/AKT phosphorylation and NOX4 expression. In Ang II-infused hypertensive mice, AP-III-a4 treatment reduced atrial enlargement, fibrosis, PI3K/AKT phosphorylation, NOX4 expression, and atrial reactive oxygen species signals; it also attenuated atrial effective refractory period shortening. AP-III-a4 significantly shortened the duration of pacing-induced AF and was associated with numerically lower AF inducibility, although the latter difference did not reach statistical significance. Collectively, these findings support the involvement of PI3K/AKT signaling in ENO1-associated regulation of NOX4 and suggest that this relationship may contribute to the observed attenuation of hypertension-associated atrial remodeling.
- Open Access
- 28 September 2026
- Published by Wolters Kluwer Health in Asian Heart Journal
- Vol. 2 (3) , 115-122
Expert recommendation on the application and development of artificial intelligence‑enhanced electrocardiography in the field of arrhythmias
Artificial intelligence‑enhanced electrocardiography (AI-ECG) is an important application of AI technology in the field of cardiovascular diseases. The popularization of AI-ECG can provide technical support for early screening, diagnosis, risk assessment, and mobile management of arrhythmia-related diseases. To promote the standardized application, dynamic evaluation, and open innovation of AI-ECG, the Chinese Heart Rhythm Society of the Chinese Society of Biomedical Engineering takes the lead and collaborates with the Chinese Society of Cardiology of the Chinese Medical Association to organize cardiovascular specialists, artificial intelligence, biomedical engineering, clinical research, and medical ethics experts. Based on evidence-based research at home and abroad, after multiple rounds of expert discussions and Delphi voting, expert recommendations are finally jointly formulated. This proposal proposes 16 core recommendations, providing a guiding framework for the development and clinical practice of AI-ECG-related products. In addition, the proposal also elaborates on the technical specifications, application scenarios, management standards, ethical supervision, and future development directions of AI-ECG, thereby promoting the comprehensive improvement of intelligent diagnosis and treatment of arrhythmia. Unlike traditional consensus and guidelines that rely heavily on GRADE evidence levels, this recommendation combines medical evidence-based assessment with medical device engineering standards and international artificial intelligence regulatory frameworks, providing a reference for the development of artificial intelligence guidelines or consensus in the medical field. Practice guideline registration: International Practice Guide Registration and Transparency Platform (PREPARE-2026CN080).
- 28 September 2026
- Published by Wolters Kluwer Health in Asian Heart Journal
- Vol. 2 (3) , 115-122
Open AccessExpert recommendation on the application and development of artificial intelligence‑enhanced electrocardiography in the field of arrhythmias
Artificial intelligence‑enhanced electrocardiography (AI-ECG) is an important application of AI technology in the field of cardiovascular diseases. The popularization of AI-ECG can provide technical support for early screening, diagnosis, risk assessment, and mobile management of arrhythmia-related diseases. To promote the standardized application, dynamic evaluation, and open innovation of AI-ECG, the Chinese Heart Rhythm Society of the Chinese Society of Biomedical Engineering takes the lead and collaborates with the Chinese Society of Cardiology of the Chinese Medical Association to organize cardiovascular specialists, artificial intelligence, biomedical engineering, clinical research, and medical ethics experts. Based on evidence-based research at home and abroad, after multiple rounds of expert discussions and Delphi voting, expert recommendations are finally jointly formulated. This proposal proposes 16 core recommendations, providing a guiding framework for the development and clinical practice of AI-ECG-related products. In addition, the proposal also elaborates on the technical specifications, application scenarios, management standards, ethical supervision, and future development directions of AI-ECG, thereby promoting the comprehensive improvement of intelligent diagnosis and treatment of arrhythmia. Unlike traditional consensus and guidelines that rely heavily on GRADE evidence levels, this recommendation combines medical evidence-based assessment with medical device engineering standards and international artificial intelligence regulatory frameworks, providing a reference for the development of artificial intelligence guidelines or consensus in the medical field. Practice guideline registration: International Practice Guide Registration and Transparency Platform (PREPARE-2026CN080).
- Open Access
- 7 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7945
NEAT1 Coordinates a PDLIM5–CACNA1C Regulatory Program Associated with a Potentially Arrhythmogenic Cardiomyocyte State in the Border Zone During Early Myocardial Infarction
Patients with early-stage myocardial infarction (MI) are at high risk of malignant ventricular arrhythmias, yet the cell-type-specific molecular landscape associated with post-infarction arrhythmogenesis has not been systematically characterized. This study integrates single-nucleus and spatial transcriptomics to define a cardiomyocyte subpopulation in early MI and dissect the NEAT1-centered regulatory network driving its ion channel remodeling. Single-nucleus transcriptomic data from post-MI human hearts were re-analyzed to identify a distinct subpopulation, termed arrhythmia-potential cardiomyocytes (aCMs), within the infarct border zone, characterized by pronounced ion channel remodeling. Gene co-expression network analysis revealed two modules highly associated with aCMs, in which NEAT1 correlated with the calcium channel gene CACNA1C and the LIM domain protein PDLIM5. All three genes were upregulated in hypoxic rat cardiomyocytes; siRNA-mediated knockdown confirmed that NEAT1 silencing downregulated CACNA1C and PDLIM5 expression, consistent with in silico knockout predictions. A ceRNA network further identified hsa-miR-204-5p/211-5p as a key mediator consistent with regulatory axis. These findings suggest that cardiomyocytes in the early MI border zone exhibit ion channel remodeling driven by elevated NEAT1, which may modulate CACNA1C and PDLIM5 through a microRNA-mediated ceRNA network, suggesting that targeting NEAT1 may warrant further investigation for preventing malignant arrhythmias in early-stage MI.
- 7 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7945
Open AccessNEAT1 Coordinates a PDLIM5–CACNA1C Regulatory Program Associated with a Potentially Arrhythmogenic Cardiomyocyte State in the Border Zone During Early Myocardial Infarction
Patients with early-stage myocardial infarction (MI) are at high risk of malignant ventricular arrhythmias, yet the cell-type-specific molecular landscape associated with post-infarction arrhythmogenesis has not been systematically characterized. This study integrates single-nucleus and spatial transcriptomics to define a cardiomyocyte subpopulation in early MI and dissect the NEAT1-centered regulatory network driving its ion channel remodeling. Single-nucleus transcriptomic data from post-MI human hearts were re-analyzed to identify a distinct subpopulation, termed arrhythmia-potential cardiomyocytes (aCMs), within the infarct border zone, characterized by pronounced ion channel remodeling. Gene co-expression network analysis revealed two modules highly associated with aCMs, in which NEAT1 correlated with the calcium channel gene CACNA1C and the LIM domain protein PDLIM5. All three genes were upregulated in hypoxic rat cardiomyocytes; siRNA-mediated knockdown confirmed that NEAT1 silencing downregulated CACNA1C and PDLIM5 expression, consistent with in silico knockout predictions. A ceRNA network further identified hsa-miR-204-5p/211-5p as a key mediator consistent with regulatory axis. These findings suggest that cardiomyocytes in the early MI border zone exhibit ion channel remodeling driven by elevated NEAT1, which may modulate CACNA1C and PDLIM5 through a microRNA-mediated ceRNA network, suggesting that targeting NEAT1 may warrant further investigation for preventing malignant arrhythmias in early-stage MI.
- 2 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (11) , 2015-2026
Comparison of the 2016 ASE/EACVI and 2025 ASE guidelines for assessing left atrial pressure in patients with normal left ventricular ejection fraction
Aims: The assessment of diastolic dysfunction in patients is clinically challenging. The 2025 American Society of Echocardiography (ASE) guidelines for assessment of left atrial pressure (LAP) were published recently and their diagnostic performance needs further validation. This study aimed to evaluate the diagnostic performance of the 2025 ASE guidelines for assessment of LAP and to compare it with that of the 2016 ASE/EACVI guidelines. Methods and results: This study prospectively collected echocardiographic data and LAP measurements from 119 patients. Patients were categorized into elevated left atrial pressure (ELAP) (LAP > 15 mm Hg) and normal (LAP ≤ 15 mm Hg) groups. Both the 2016 ASE/EACVI and 2025 ASE guidelines were applied to assess diastolic function using echocardiographic parameters. The 2025 guidelines demonstrated significantly higher sensitivity (86.4% [75.7–93.6] vs. 54.0% [39.3–68.2]) and feasibility (100% [98.0–100] vs. 78.1% [72.2–84.0]) but lower specificity (81.8% [73.8–88.2] vs. 94.8% [88.3–98.3]) and positive predictive value (72.2% [63.7–79.3] vs. 84.4% [68.9–92.9]) compared with the 2016 guidelines. Negative predictive value (91.7% [85.6–95.3] vs. 79.8% [74.5–84.3]) and overall accuracy (83.4% [77.3–88.5] vs. 80.8% [73.5–86.9]) improved modestly. Conclusion: The 2025 guidelines significantly improved the feasibility of assessing LAP and enhanced ELAP detection rates and applicability while maintaining comparable accuracy.
- 2 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (11) , 2015-2026
Comparison of the 2016 ASE/EACVI and 2025 ASE guidelines for assessing left atrial pressure in patients with normal left ventricular ejection fraction
Aims: The assessment of diastolic dysfunction in patients is clinically challenging. The 2025 American Society of Echocardiography (ASE) guidelines for assessment of left atrial pressure (LAP) were published recently and their diagnostic performance needs further validation. This study aimed to evaluate the diagnostic performance of the 2025 ASE guidelines for assessment of LAP and to compare it with that of the 2016 ASE/EACVI guidelines. Methods and results: This study prospectively collected echocardiographic data and LAP measurements from 119 patients. Patients were categorized into elevated left atrial pressure (ELAP) (LAP > 15 mm Hg) and normal (LAP ≤ 15 mm Hg) groups. Both the 2016 ASE/EACVI and 2025 ASE guidelines were applied to assess diastolic function using echocardiographic parameters. The 2025 guidelines demonstrated significantly higher sensitivity (86.4% [75.7–93.6] vs. 54.0% [39.3–68.2]) and feasibility (100% [98.0–100] vs. 78.1% [72.2–84.0]) but lower specificity (81.8% [73.8–88.2] vs. 94.8% [88.3–98.3]) and positive predictive value (72.2% [63.7–79.3] vs. 84.4% [68.9–92.9]) compared with the 2016 guidelines. Negative predictive value (91.7% [85.6–95.3] vs. 79.8% [74.5–84.3]) and overall accuracy (83.4% [77.3–88.5] vs. 80.8% [73.5–86.9]) improved modestly. Conclusion: The 2025 guidelines significantly improved the feasibility of assessing LAP and enhanced ELAP detection rates and applicability while maintaining comparable accuracy.
- Open Access
- 2 June 2026
- Published by Elsevier in JACC: Case Reports
- p. 108475
Open-Irrigated Helical Radiofrequency Septal Ablation for Obstructive Hypertrophic Cardiomyopathy
- 2 June 2026
- Published by Elsevier in JACC: Case Reports
- p. 108475
Open AccessOpen-Irrigated Helical Radiofrequency Septal Ablation for Obstructive Hypertrophic Cardiomyopathy
- Open Access
- 3 February 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (2)
Three-year clinical outcomes of left atrial appendage occlusion with or without ablation: insight from the RECORD study
The long-term impact of left atrial appendage occlusion (LAAO) plus ablation for atrial fibrillation remains controversial. The present study aims to compare the three-year clinical outcomes of LAAO patients with or without one-staged ablation. The RECORD study (NCT03917563) was a prospective registry conducted in 39 participating sites in China between 1 April 2019 and 31 October 2020, which consecutively enrolled 3082 patients who successfully received the WATCHMAN LAAO device. The current study compared patients who received LAAO only to patients who underwent LAAO plus ablation. A 1:1 propensity score matching was performed to attenuate confounding. The primary outcome was a composite endpoint of cardiovascular death, stroke, and systemic embolism at 3-year. 1633/2928 (55.8%) patients received LAAO only and 1295/2928 (44.2%) received LAAO plus ablation. After propensity score matching, 1016/2032 (50.0%) were in the LAAO group and 1016/2032 (50.0%) in the LAAO plus ablation group. The mean ± SD age was 68.8 ± 9.3 years, with 815 (40.1%) participants being female. The mean ± SD CHA2DS2-VASc and HAS-BLED scores at baseline were 3.9 ± 1.8 and 2.4 ± 1.1, respectively. At three-year, compared to LAAO only, LAAO plus ablation was associated with a lower risk of cardiovascular death, stroke, systemic embolism (6.9%vs.10.4%, HRPSM:0.66, 95%CI: 0.49–0.89, P = 0.007), which was driven mainly by the lower risk of cardiovascular death (3.7% vs. 7.3%, HRPSM: 0.50, 95%CI: 0.34–0.74, P = 0.001). No significant between-group differences were noted for BARC-defined bleeding. LAAO plus ablation was associated with a lower risk of a composite of cardiovascular death, stroke, and systemic embolism than LAAO only at 3-year. However, given the observational nature of the current study, the results should be considered as hypothesis-generating only.
- 3 February 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (2)
Open AccessThree-year clinical outcomes of left atrial appendage occlusion with or without ablation: insight from the RECORD study
The long-term impact of left atrial appendage occlusion (LAAO) plus ablation for atrial fibrillation remains controversial. The present study aims to compare the three-year clinical outcomes of LAAO patients with or without one-staged ablation. The RECORD study (NCT03917563) was a prospective registry conducted in 39 participating sites in China between 1 April 2019 and 31 October 2020, which consecutively enrolled 3082 patients who successfully received the WATCHMAN LAAO device. The current study compared patients who received LAAO only to patients who underwent LAAO plus ablation. A 1:1 propensity score matching was performed to attenuate confounding. The primary outcome was a composite endpoint of cardiovascular death, stroke, and systemic embolism at 3-year. 1633/2928 (55.8%) patients received LAAO only and 1295/2928 (44.2%) received LAAO plus ablation. After propensity score matching, 1016/2032 (50.0%) were in the LAAO group and 1016/2032 (50.0%) in the LAAO plus ablation group. The mean ± SD age was 68.8 ± 9.3 years, with 815 (40.1%) participants being female. The mean ± SD CHA2DS2-VASc and HAS-BLED scores at baseline were 3.9 ± 1.8 and 2.4 ± 1.1, respectively. At three-year, compared to LAAO only, LAAO plus ablation was associated with a lower risk of cardiovascular death, stroke, systemic embolism (6.9%vs.10.4%, HRPSM:0.66, 95%CI: 0.49–0.89, P = 0.007), which was driven mainly by the lower risk of cardiovascular death (3.7% vs. 7.3%, HRPSM: 0.50, 95%CI: 0.34–0.74, P = 0.001). No significant between-group differences were noted for BARC-defined bleeding. LAAO plus ablation was associated with a lower risk of a composite of cardiovascular death, stroke, and systemic embolism than LAAO only at 3-year. However, given the observational nature of the current study, the results should be considered as hypothesis-generating only.
- Open Access
- 31 January 2026
- Published by Wiley in Advanced Science
- Vol. 13 (19) , e16090
Connexin43 Deficiency Leads to Ventricular Arrhythmias by Reprogramming Proline Metabolism
Ventricular arrhythmias (VAs) as life‐threatening heart rhythm disorders, reduced connexin43 (Cx43) is one of the mechanisms of VAs. Cx43 is the predominant ventricular gap junction protein essential for cardiac electrical conduction; the absence in the mouse heart results in sudden arrhythmic death. However, the mechanism linking Cx43 downregulation and VA formation remains unclear. Here it is aimed to elucidate the molecular mechanism by which Cx43 deficiency leads to VAs using Cx43 knockout (Cx43‐KO) induced pluripotent stem‐derived cardiomyocytes and cardiac‐specific conditional Cx43‐KO (Cx43‐cKO) mice. It is shown that Cx43‐KO induced arrhythmic phenotype and decreased proline content both in vitro and in vivo. Mechanistically, Cx43 interacts with the amino acid transporter SNAT2 (sodium‐dependent neutral amino acid transporter). Cx43 deficiency reduces SNAT2 expression, impairing proline transport and metabolism. This disruption leads to mitochondrial dysfunction, oxidative stress, abnormal calcium handling, and arrhythmias. Exogenous proline supplementation rescued the arrhythmic phenotype in Cx43‐cKO mice by restoring metabolic balance. In conclusion, it is suggested that Cx43 deficiency leads to VAs through SNAT2‐mediated proline metabolic reprogramming. Targeting proline metabolism may therefore offer novel therapeutic strategies for VAs.
- 31 January 2026
- Published by Wiley in Advanced Science
- Vol. 13 (19) , e16090
Open AccessConnexin43 Deficiency Leads to Ventricular Arrhythmias by Reprogramming Proline Metabolism
Ventricular arrhythmias (VAs) as life‐threatening heart rhythm disorders, reduced connexin43 (Cx43) is one of the mechanisms of VAs. Cx43 is the predominant ventricular gap junction protein essential for cardiac electrical conduction; the absence in the mouse heart results in sudden arrhythmic death. However, the mechanism linking Cx43 downregulation and VA formation remains unclear. Here it is aimed to elucidate the molecular mechanism by which Cx43 deficiency leads to VAs using Cx43 knockout (Cx43‐KO) induced pluripotent stem‐derived cardiomyocytes and cardiac‐specific conditional Cx43‐KO (Cx43‐cKO) mice. It is shown that Cx43‐KO induced arrhythmic phenotype and decreased proline content both in vitro and in vivo. Mechanistically, Cx43 interacts with the amino acid transporter SNAT2 (sodium‐dependent neutral amino acid transporter). Cx43 deficiency reduces SNAT2 expression, impairing proline transport and metabolism. This disruption leads to mitochondrial dysfunction, oxidative stress, abnormal calcium handling, and arrhythmias. Exogenous proline supplementation rescued the arrhythmic phenotype in Cx43‐cKO mice by restoring metabolic balance. In conclusion, it is suggested that Cx43 deficiency leads to VAs through SNAT2‐mediated proline metabolic reprogramming. Targeting proline metabolism may therefore offer novel therapeutic strategies for VAs.
- Open Access
- 29 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 44759
Very early cardiac hemodynamic changes after atrial fibrillation ablation
All chambers’ systolic functions were improved with long-term follow-up after catheter ablation (CA). However, changes on cardiac function on very early phase (within 48 h) has not been thoroughly investigated. This study aimed to evaluate the acute effects of CA on cardiac function and morphology immediately post-procedural (≤ 48 h). We prospectively enrolled 117 consecutive patients. Hemodynamic parameters including biatrial pressure and echocardiographic data were acquired pre- and post-ablation. (i) All bi-atrial pressures significantly elevated post-ablation (p < 0.002). (ii) Bi-atrial function including ejection fraction, reservoir strain and conduit strain improved immediately after ablation (p < 0.01). Persistent atrial fibrillation (AF) improved more than paroxysmal AF. (iii) Biventricular systolic function improved early but left ventricular diastolic function was stunned within 48 h (p < 0.01). Whereas all chambers’ volume did not change significantly (p > 0.05). (iv) No statistically significant differences in pre- versus post-procedural pressure changed between patients with persistent AF and those with paroxysmal AF in biatrial pressure elevation (p > 0.05). (v) Echocardiographic parameters including LA reservoir strain, RA reservoir strain, peak A of mitral valve, peak E of tricuspid valve and inferior vena cava diameters increased more in persistent AF groups (p < 0.05). This prospective study suggested all chambers’ systolic functions improved in early period post-ablation with left ventricular diastolic function stunning. Mechanical improvements preceding structural remodeling in AF patients early after ablation.
- 29 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 44759
Open AccessVery early cardiac hemodynamic changes after atrial fibrillation ablation
All chambers’ systolic functions were improved with long-term follow-up after catheter ablation (CA). However, changes on cardiac function on very early phase (within 48 h) has not been thoroughly investigated. This study aimed to evaluate the acute effects of CA on cardiac function and morphology immediately post-procedural (≤ 48 h). We prospectively enrolled 117 consecutive patients. Hemodynamic parameters including biatrial pressure and echocardiographic data were acquired pre- and post-ablation. (i) All bi-atrial pressures significantly elevated post-ablation (p < 0.002). (ii) Bi-atrial function including ejection fraction, reservoir strain and conduit strain improved immediately after ablation (p < 0.01). Persistent atrial fibrillation (AF) improved more than paroxysmal AF. (iii) Biventricular systolic function improved early but left ventricular diastolic function was stunned within 48 h (p < 0.01). Whereas all chambers’ volume did not change significantly (p > 0.05). (iv) No statistically significant differences in pre- versus post-procedural pressure changed between patients with persistent AF and those with paroxysmal AF in biatrial pressure elevation (p > 0.05). (v) Echocardiographic parameters including LA reservoir strain, RA reservoir strain, peak A of mitral valve, peak E of tricuspid valve and inferior vena cava diameters increased more in persistent AF groups (p < 0.05). This prospective study suggested all chambers’ systolic functions improved in early period post-ablation with left ventricular diastolic function stunning. Mechanical improvements preceding structural remodeling in AF patients early after ablation.
- Open Access
- 15 September 2025
- Published by Wiley in Advanced Science
- Vol. 12 (45) , e12058
Decreased RYR2 Cluster Size and Abnormal SR Ca 2+ Release Contribute to Arrhythmogenesis in TMEM43 ‐Related ARVC
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare inherited cardiomyopathy featured by life‐threatening arrhythmias. While TMEM43 has been identified as an ARVC‐associated gene, molecular links between TMEM43 mutations and electrophysiological abnormalities in ARVC remain largely elusive. Here, using induced‐pluripotent‐stem‐cell‐derived cardiomyocytes (iPSC‐CMs) and knock‐in mice as models, it is demonstrated that a novel TMEM43 mutation (TMEM43‐P386S) causes Ca 2+ dysregulation that leads to arrhythmic phenotypes in ARVC, which can be prevented by flecainide. Mechanistically, TMEM43 interacts with lamin B2, and the TMEM43‐P386S mutation induces lamin B2 mislocalization and abnormal nuclear envelope structure in ARVC iPSC‐CMs, resulting in decreased chromatin opening of promoters associated with downregulated genes, including ryanodine receptor 2 ( RYR2 ). RYR2 s are downregulated and grouped into smaller clusters in ARVC iPSC‐CMs, as revealed by Tau‐STED super‐resolution imaging, contributing to enhanced RYR2 ‐mediated sarcoplasmic reticulum Ca 2+ leak. These findings represent a novel mechanism underlying arrhythmogenesis in TMEM43 ‐related ARVC and point to RYR2 stabilization as a potential therapeutic strategy.
- 15 September 2025
- Published by Wiley in Advanced Science
- Vol. 12 (45) , e12058
Open AccessDecreased RYR2 Cluster Size and Abnormal SR Ca 2+ Release Contribute to Arrhythmogenesis in TMEM43 ‐Related ARVC
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare inherited cardiomyopathy featured by life‐threatening arrhythmias. While TMEM43 has been identified as an ARVC‐associated gene, molecular links between TMEM43 mutations and electrophysiological abnormalities in ARVC remain largely elusive. Here, using induced‐pluripotent‐stem‐cell‐derived cardiomyocytes (iPSC‐CMs) and knock‐in mice as models, it is demonstrated that a novel TMEM43 mutation (TMEM43‐P386S) causes Ca 2+ dysregulation that leads to arrhythmic phenotypes in ARVC, which can be prevented by flecainide. Mechanistically, TMEM43 interacts with lamin B2, and the TMEM43‐P386S mutation induces lamin B2 mislocalization and abnormal nuclear envelope structure in ARVC iPSC‐CMs, resulting in decreased chromatin opening of promoters associated with downregulated genes, including ryanodine receptor 2 ( RYR2 ). RYR2 s are downregulated and grouped into smaller clusters in ARVC iPSC‐CMs, as revealed by Tau‐STED super‐resolution imaging, contributing to enhanced RYR2 ‐mediated sarcoplasmic reticulum Ca 2+ leak. These findings represent a novel mechanism underlying arrhythmogenesis in TMEM43 ‐related ARVC and point to RYR2 stabilization as a potential therapeutic strategy.